CALYPTE BIOMEDICAL CORPORATION
83,056,050 Shares of Common Stock, $0.03 Par Value
o This Prospectus relates to the resale of our common stock by the selling security holders, all of whom were issued securities pursuant to an exemption under Regulation S, except for the selling security holders in the May 2004 PIPE who were issued securities pursuant to an exemption under Regulation D, of up to:
o 3,088,554 shares of our common stock that have previously been issued to certain selling security holders as a result of their conversions of $3,232,000 aggregate original principal amount of our 8% secured convertible notes, plus interest and liquidated damages;
o 4,725,414 shares of our common stock, including 563,538 shares that may be issued upon the conversion of the remaining $91,597 aggregate principal amount of our 10% convertible debentures, including accrued interest, extension fees and other amounts, and 4,161,876 shares that have been previously issued to a selling security holder upon the conversion of $1,100,072 principal amount of our 10% convertible debentures, plus accrued interest and liquidated damages;
o 10,351,061 shares of our common stock, including 682,646 shares that may be issued upon the conversion of the remaining $66,113 aggregate principal amount of our 12% convertible debentures including accrued interest and other amounts, 100,000 shares of common stock underlying warrants issued as part of the consideration for a 12% convertible debenture transaction, and 9,568,415 shares previously issued to certain selling security holders upon their conversions of $1,933,887 aggregate principal amount of our 12% convertible debentures, plus accrued interest and liquidated damages;
o 28,333,333 shares of our common stock that have previously been issued to a selling security holder in connection with a $2,500,000 PIPE transaction at $0.30 per share and a $10,000,000 PIPE transaction at $0.50 per share;
o 3,265,188 shares of our common stock, including 2,569,727 shares that have previously been issued to certain selling security holders in connection with agreements in which we have obtained goods and services in return for the issuance of shares of our common stock, and 695,461 shares underlying warrants or other agreements between us and certain selling security holders in connection with which we have obtained goods and services;
o 1,275,000 shares of our common stock underlying warrants issued in connection with a $10,000,000 5% Promissory Note Commitment Agreement and subsequent amendments thereof; and
o 32,017,500 shares of our common stock, including 23,250,000 shares that have been previously issued to selling security holders in connection with a $9,300,000 May 2004 PIPE transaction at $0.40 per share and an additional 8,767,500 shares underlying warrants to purchase our common stock at $0.50 per share issued in conjunction therewith.
o We will not receive any proceeds from the sale of these shares. We will receive proceeds from the exercise of warrants issued to certain of the selling stockholders. Any proceeds received will be used for general corporate purposes.
es ist schon vom 29.07.
da sind teilweise weitere shares, die im filing für die HJ-zahlen noch nicht drin waren...
hier der link dazu:
http://www.pinksheets.com/quote/...2004%255C07%255C09%255C&symbol=HIV
|
Thread abonnieren
hättest du gesehen das ich in frankfurt nachgekauft hatte zu 0,38 EURO.dafür sind die heute auch wieder wech gegangen. 
